3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
6
Prostatic Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Oropharyngeal Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Breast Neoplasms
3
Weight Loss
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Recurrence
2
Myasthenia Gravis
2
Mouth Neoplasms
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma
2
Cachexia
2
Anorexia
2
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphangioma, Cystic
×
30 days
×
Clear all
NCT05948943
2026-06-02
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled